Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID S RUSSELL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1548241839
CMS profile
251083
Location
NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$42,702.52

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $25,046.34 26
Neurocrine Biosciences, Inc. $12,538.29 22
Biogen, Inc. $3,545.33 3
JAZZ PHARMACEUTICALS INC. $1,500.00 2
GE HealthCare $72.56 1

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID S RUSSELL

NPI 1548241839 · CMS profile ID 251083

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548241839?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID S RUSSELL, NPI 1548241839, CMS profile ID 251083. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548241839?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID S RUSSELL, NPI 1548241839, CMS profile ID 251083. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548241839?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID S RUSSELL, NPI 1548241839, CMS profile ID 251083, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1548241839?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $42,702.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Neurocrine Biosciences, Inc. $57.6104/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052143637 CMS
Neurocrine Biosciences, Inc. $123.6601/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052143621 CMS
Neurocrine Biosciences, Inc. $2,925.0001/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052143625 CMS
Neurocrine Biosciences, Inc. $1,055.1101/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052143629 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,593.20 43
PY2020 $3,743.36 6
PY2021 $16,201.03 20
PY2022 $14,949.04 20
PY2023 $42,702.52 54
PY2024 $67,645.87 75
PY2025 $40,928.59 46

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,074,783.10 37
PY2024 Recipient $5,636.00 1
PY2024 Principal investigator $2,082,872.67 80
PY2023 Recipient $786.94 2
PY2023 Principal investigator $2,474,220.91 71
PY2022 Recipient $5,615.00 4
PY2022 Principal investigator $3,225,081.73 55
PY2021 Recipient $2,670.79 2
PY2021 Principal investigator $2,550,674.67 55
PY2020 Recipient $8,296.08 5
PY2020 Principal investigator $10,800,724.16 131
PY2019 Recipient $5,346.91 2
PY2019 Principal investigator $8,748,084.16 97

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $1,176.30 12/15/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559232
Principal investigator 1 Eisai Inc. $1,196.10 11/17/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559230
Principal investigator 1 Roche TCRC, Inc. $1,746.00 11/13/2025 Non-covered Recipient Entity
Invicro LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211617575
Principal investigator 1 Eisai Inc. $2,399.40 10/20/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559234
Principal investigator 1 Roche TCRC, Inc. $450.00 10/15/2025 Non-covered Recipient Entity
Invicro LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211617566
Principal investigator 1 Roche TCRC, Inc. $30,034.80 10/15/2025 Non-covered Recipient Entity
Invicro LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211617571
Principal investigator 1 Eisai Inc. $150.00 09/15/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559222
Principal investigator 1 Roche TCRC, Inc. $18,509.40 09/11/2025 Non-covered Recipient Entity
Invicro LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211617559
Principal investigator 1 Roche TCRC, Inc. $24,796.80 08/14/2025 Non-covered Recipient Entity
Invicro LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211617563
Principal investigator 1 Eisai Inc. $4,228.20 08/11/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559224
Principal investigator 1 Eisai Inc. $2,352.60 07/21/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559220
Principal investigator 1 Eisai Inc. $420.00 07/21/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559228
Principal investigator 1 Eisai Inc. $2,352.60 07/07/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559226
Principal investigator 1 Roche TCRC, Inc. $34,241.40 06/13/2025 Non-covered Recipient Entity
Invicro LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211617555
Principal investigator 1 Eli Lilly and Company $2.69 06/04/2025 Non-covered Recipient Entity
INVICRO
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187882190
Principal investigator 1 Eli Lilly and Company $28.44 04/30/2025 Non-covered Recipient Entity
INVICRO
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187882192
Principal investigator 1 Eli Lilly and Company $373,405.00 04/22/2025 Non-covered Recipient Entity
INVICRO
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884980
Principal investigator 1 Eli Lilly and Company $6,234.20 04/14/2025 Non-covered Recipient Entity
INVICRO
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883580
Principal investigator 1 Roche TCRC, Inc. $282.00 03/27/2025 Non-covered Recipient Entity
INSTITUTE FOR NEURODEGENERATIVE DISORDERS
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211616052
Principal investigator 1 Roche TCRC, Inc. $111.60 03/27/2025 Non-covered Recipient Entity
Invicro LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211617547
Principal investigator 1 Eisai Inc. $7,803.90 03/18/2025 Non-covered Recipient Entity
INVICRO LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559238
Principal investigator 1 Eli Lilly and Company $1,265.27 02/25/2025 Non-covered Recipient Entity
INSTITUTE FOR NEURODEGENERATIVE DISORDERS
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883556
Principal investigator 1 Eli Lilly and Company $5,660.81 02/25/2025 Non-covered Recipient Entity
MEMORY ENHANCEMENT CENTER OF AMERICA INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187886712
Principal investigator 1 ABBVIE INC. $3,000.00 02/12/2025 Non-covered Recipient Entity
INVICRO LLC
M23-471 - M23-471 Ph1b Target Occupancy PET No dispute reported 06/30/2026 1202450626
Principal investigator 1 Eli Lilly and Company $215,507.19 02/11/2025 Non-covered Recipient Entity
INVICRO
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187881994
Principal investigator 1 Eli Lilly and Company $2,865.90 02/10/2025 Non-covered Recipient Entity
INVICRO
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187882188
Principal investigator 1 Genentech, Inc. $56,986.00 02/04/2025 Non-covered Recipient Entity
INSTITUTE FOR NEURODEGENERATIVE DISORDERS
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211616048
Principal investigator 1 Roche TCRC, Inc. $4,400.00 01/30/2025 Non-covered Recipient Entity
INSTITUTE FOR NEURODEGENERATIVE DISORDERS
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211616056
Principal investigator 1 Eli Lilly and Company $10,657.00 01/28/2025 Non-covered Recipient Entity
INSTITUTE FOR NEURODEGENERATIVE DISORDERS
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187883554
Principal investigator 1 Eli Lilly and Company $840.75 01/27/2025 Non-covered Recipient Entity
MEMORY ENHANCEMENT CENTER OF AMERICA INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187884920
Principal investigator 1 Eisai Inc. $2,352.60 01/21/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244559218
Principal investigator 1 Eli Lilly and Company $53,075.00 01/21/2025 Non-covered Recipient Entity
INVICRO
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187881992
Principal investigator 1 Eli Lilly and Company $38,405.00 01/21/2025 Non-covered Recipient Entity
INSTITUTE FOR NEURODEGENERATIVE DISORDERS
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884012
Principal investigator 1 Roche TCRC, Inc. $53,978.77 01/16/2025 Non-covered Recipient Entity
INSTITUTE FOR NEURODEGENERATIVE DISORDERS
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211616061
Principal investigator 1 Roche TCRC, Inc. $29,877.30 01/16/2025 Non-covered Recipient Entity
Invicro LLC
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211617551
Principal investigator 1 Eli Lilly and Company $344.08 01/09/2025 Non-covered Recipient Entity
INSTITUTE FOR NEURODEGENERATIVE DISORDERS
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187883860
Principal investigator 1 Biogen, Inc. $83,646.00 01/03/2025 Non-covered Recipient Entity
Institute For Neurodegenerative Disorder
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1236946990